ArticleInternational journal of cardiology2015
Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure.
Article in International journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05335629 (Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Effects of aerobic and resistance exercises on cardiovascular biomarkers in sedentary females: a randomized controlled trial.BMC sports science, medicine & rehabilitation · 2026Article
- Assessment and diagnosis of right ventricular failure-retrospection and future directions.Frontiers in cardiovascular medicine · 2023Review
- Beyond the Finish Line: The Impact and Dynamics of Biomarkers in Physical Exercise-A Narrative Review.Journal of clinical medicine · 2021Review
- Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.International journal of molecular sciences · 2021Review
- Elevated levels of soluble ST2 but not galectin-3 are associated with increased risk of mortality in hemodialysis patients.Kidney research and clinical practice · 2021Article
- Inhibition of NF-Journal of immunology research · 2021Article
- Diagnosis and treatment of right ventricular dysfunction in congenital heart disease.Cardiovascular diagnosis and therapy · 2020Review
- Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery-Are We There Yet?Journal of clinical medicine · 2019Review
- Exercise-induced Changes in Soluble ST2 Concentrations in Marathon Runners.Medicine and science in sports and exercise · 2019Article
- GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.Journal of cellular and molecular medicine · 2018Article
- Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device.European journal of clinical investigation · 2018Article
- Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy.Journal of cellular and molecular medicine · 2017Article
- The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy.Journal of cardiovascular translational research · 2017Article
- Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy.Scientific reports · 2017Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElevated levels of soluble ST2 (sST2) are associated with adverse outcome in heart failure. A change in sST2 levels has also been shown to presage outcome. In vitro, ST2 expression is induced by myocardial stress and pro-inflammatory stimuli. The determinants of sST2 levels in vivo, and how they vary with clinical status over time, have not been well described. In a cohort of patients with non-ischemic heart failure, we aimed to assess the association between sST2-levels and hemodynamic parameters reflecting right and left ventricular pre- and afterload, and how these vary with time and clinical status.
methodsWe prospectively recruited 102 patients with a left ventricular ejection fraction of 26 ± 10% and a diagnosis of idiopathic dilated cardiomyopathy based on patient history, clinical examination, echocardiography and coronary angiography. Patients went through extensive baseline work-up and were re-examined after one year. Subsequently, heart transplantations and deaths were recorded. Determinants of sST2 were analyzed at baseline and after one year. Soluble ST2 was measured with a highly sensitive immunoassay.
resultsSoluble ST2 levels were associated with hemodynamic parameters, but these associations were attenuated with clinical improvement. Soluble ST2 was elevated in patients with severe symptoms, but did not vary with etiology, viral presence or the amount of myocardial fibrosis. Heart rate and right atrial pressure remained independent predictors of sST2 on multiple regression analysis.
conclusionsOur results imply that in non-ischemic heart failure, sST2 reflects hemodynamic stress rather than pathogenic processes in the myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.